Company intelligence / Profile preview

Alivio Therapeutics

Boston, Massachusetts, United Statespabstpatent.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

Alivio Therapeutics developed a proprietary inflammation-targeting hydrogel platform designed to deliver immunoregulatory drugs directly to inflamed tissues, enabling localized immune modulation with reduced systemic side effects. The company’s approach showed promise in multiple preclinical models across various inflammatory diseases but all known development programs have since been discontinued following its acquisition by PureTech in June 2021. No active clinical trials or commercial products are reported.

Therapeutic areas: GastroenterologyNephrology
Modalities: Hydrogel-based drug delivery therapySmall molecule
Industry: Biotech

Drug pipeline

1 asset

ALV-107

Pre-clinical

Indications: Interstitial cystitis/bladder pain syndrome

Beyond the preview

Go deeper on Alivio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alivio Therapeutics.

Explore the full profile